Geron to Participate at Upcoming Investor Conferences in April

Rhea-AI Summary

Geron (GERN) announces CEO's participation in upcoming virtual investor conferences. John A. Scarlett, M.D., to present at Needham Virtual Healthcare Conference and Stifel's Targeted Oncology Days. Webcasts will be available on the company's website.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to present at the following virtual investor conferences:

• 23^rd Annual Needham Virtual Healthcare Conference
  Wednesday, April 10^th at 10:15 a.m. ET (Fireside Chat)
  
  
• Stifel’s 2024 Virtual Targeted Oncology Days
  Wednesday, April 17^th at 11:30 a.m. ET (Corporate Presentation)

A webcast of each fireside chat and corporate presentation will be available through the Investor Relations section of the Company’s website under Events. An archive of the webcast will be available on the Company’s website for 30 days.

About Geron

Geron is a late-stage clinical biopharmaceutical company pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic malignancies. Our first-in-class investigational telomerase inhibitor, imetelstat, harnesses Nobel Prize-winning science in a treatment that may alter the underlying drivers of disease. The New Drug Application (NDA) for imetelstat for the treatment of transfusion dependent anemia in patients with lower-risk myelodysplastic syndromes (TD LR-MDS) who have failed to respond or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs), based on the results from the Phase 3 IMerge clinical trial, is currently under review by the United States Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of June 16, 2024. In addition, an MAA is under review in the European Union for the same proposed indication. Furthermore, Geron currently has an ongoing pivotal Phase 3 clinical trial evaluating imetelstat in relapsed/refractory myelofibrosis (R/R MF). To learn more, visit www.geron.com or follow us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240403337301/en/

Aron Feingold

Vice President, Investor Relations and Corporate Communications

Kristen Kelleher

Associate Director, Investor Relations and Corporate Communications

investor@geron.com

media@geron.com

Source: Geron Corporation

FAQ

When is John A. Scarlett, M.D., scheduled to present at the 23rd Annual Needham Virtual Healthcare Conference?

John A. Scarlett, M.D., is scheduled to present at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10th at 10:15 a.m. ET.

What is the date and time for John A. Scarlett, M.D.'s presentation at Stifel's 2024 Virtual Targeted Oncology Days?

John A. Scarlett, M.D., will present at Stifel's 2024 Virtual Targeted Oncology Days on Wednesday, April 17th at 11:30 a.m. ET.

Where can the webcast of the fireside chat and corporate presentation be accessed?

The webcast of the fireside chat and corporate presentation can be accessed through the Investor Relations section of Geron 's website under Events.

How long will the archive of the webcast be available on Geron 's website?

The archive of the webcast will be available on Geron 's website for 30 days.